MyFinsight
Home
Blog
About
Contact
Download
Download image
Depreciation and
amortization
$60,743K
Proceeds from the sale and
maturity of marketable...
$323,595K
Share based
compensation
$44,868K
Accrued expenses
$28,840K
Inventory
-$5,016K
Amortization of debt discount
and issuance costs
$1,640K
Income taxes
-$849K
Loss on allowance for
inventory
$684K
Net cash provided by
(used in) operating...
$37,784K
Net cash provided by
(used in) investing...
$27,892K
Canceled cashflow
$104,856K
Canceled cashflow
$295,703K
Net cash provided by
(used) in operating...
$37,784K
Net cash provided by
investing activities
$27,892K
Effect of exchange rate
changes on cash
$2,291K
Net loss from
continuing operations
-$50,261K
Accounts receivable
$27,822K
Other current and
non-current liabilities
-$9,700K
Prepaid expenses and
other current and...
$7,658K
Amortization of discounts on
investments
$4,436K
Deferred revenue,
current and non-current
-$2,815K
Other
$1,457K
Change in lease assets
and liabilities,...
-$622K
Accounts payable
-$85K
Purchase of marketable
debt securities
$237,142K
Purchase of intangible
assets
$58,157K
Other
$404K
Net increase
(decrease) in cash and cash...
$34,500K
Canceled cashflow
$33,467K
Net cash (used in)
provided by financing...
-$33,467K
Proceeds from exercise of
stock options
$34,745K
Proceeds from the
issuances under the...
$2,792K
Net cash (used in)
provided by financing...
-$33,467K
Canceled cashflow
$37,537K
Repayment of 2025
convertible senior notes
$68,904K
Payment of guaranteed
minimum royalty
$2,100K
Back
Back
Cash Flow
source: myfinsight.com
Travere Therapeutics, Inc. (TVTX)
Travere Therapeutics, Inc. (TVTX)